{"id":61380,"date":"2025-06-05T19:06:19","date_gmt":"2025-06-05T17:06:19","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/"},"modified":"2025-06-05T19:06:19","modified_gmt":"2025-06-05T17:06:19","slug":"wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/","title":{"rendered":"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio"},"content":{"rendered":"
\n

SWEDESBORO, N.J.–(BUSINESS WIRE)–#AnimalHealth<\/a>–Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source backed by pharmacist support and FDA-registered ingredient sourcing.<\/p>\n

<\/a>
<\/a><\/p>\n

\nGS-441524 can be compounded as a 50mg\/ml flavored oral oil suspension in multiple sizes, to improve compliance and ease of administration. The addition complements Wedgewood\u2019s Molnupiravir formulations, giving veterinarians access to two antivirals with distinct mechanisms of action.<\/p>\n

\n\u201cFIP is one of the toughest diagnoses we face, not just clinically, but emotionally too,\u201d said Dr. Rae Hutchins, Chief Veterinary Officer at Wedgewood. \u201cFor a long time, vets had to deal with inconsistent access and quality when it came to GS-441524. Now, by offering both GS-441524 and Molnupiravir from one trusted, pharmacist-supported source, we\u2019re making it easier for veterinarians to focus on what matters most, giving their patients the best possible chance.\u201d<\/p>\n

\n“Having access to both GS-441524 and Molnupiravir compounded formulations through Wedgewood not only widens access to affordable FIP treatment across the US, but it also gives veterinarians the ability to easily choose and adapt treatment to best suit the needs of their patients and clients,\u201d said Nicole Jacque, co-founder of FIP Global Cats. \u201cHaving pharmacists who understand the urgency and complexity of these cases partnering with veterinarians is key to ensuring the best treatment outcomes for cats with FIP.\u201d<\/p>\n

\nUntil recently, many veterinarians relied on fragmented or unregulated sources for GS-441524, making it difficult to ensure consistency and continuity of care. The introduction of this option through Wedgewood reflects a direct response to those challenges, providing prescribers with a trusted, quality-assured formulation from a pharmacy they can count on.<\/p>\n

\nThe launch of GS-441524 builds on Wedgewood\u2019s long-standing role in supporting veterinarians with customized treatment solutions for complex cases. As part of its commitment to responsible compounding, the pharmacy emphasizes that its GS-441524 formulation is not approved by the FDA, has not been studied in clinical trials, and Wedgewood makes no claims of efficacy or safety. Independent third-party studies related to GS-441524 are available for veterinary reference through Wedgewood\u2019s FIP Resource Center.<\/p>\n

\nTo learn more about GS-441524 and access educational resources, visit www.Wedgewood.com\/FIP<\/a>.<\/p>\n

\nAbout Wedgewood
\n
<\/b>Wedgewood is the nation\u2019s largest and most trusted provider of compounded veterinary medications. Its next-generation home delivery platform, Blue Rabbit, streamlines patient care and marks a significant evolution in online pharmacy services. Together, Blue Rabbit and Wedgewood serve more than 70,000 veterinary professionals and more than one million animals annually. For more information visit www.Wedgewood.com<\/a>.<\/p>\n

\nAbout FIP Global Cats<\/b><\/p>\n

\nFIP Global CATS\u00ae (Community, Advocacy, Treatment, Support) is a leading organization in the fight against feline infectious peritonitis (FIP). Uniting veterinarians, researchers, and pet owners, it provides crucial support to those facing an FIP diagnosis. The organization is committed to empowering pet parents, advocating for safe, effective and affordable legal treatments, and advancing FIP research. For more information, please visit https:\/\/www.fipglobalcats.com\/<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nJennifer Ravalli
\n
jennifer.ravalli@wedgewood.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SWEDESBORO, N.J.–(BUSINESS WIRE)–#AnimalHealth–Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61380","6":"format-standard","7":"category-industry"},"yoast_head":"\nWedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SWEDESBORO, N.J.–(BUSINESS WIRE)–#AnimalHealth–Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-06-05T17:06:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250605659867\/en\/2490220\/22\/Logo_Wedgewood.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio\",\"datePublished\":\"2025-06-05T17:06:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/\"},\"wordCount\":542,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250605659867\\\/en\\\/2490220\\\/22\\\/Logo_Wedgewood.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/\",\"name\":\"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250605659867\\\/en\\\/2490220\\\/22\\\/Logo_Wedgewood.jpg\",\"datePublished\":\"2025-06-05T17:06:19+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250605659867\\\/en\\\/2490220\\\/22\\\/Logo_Wedgewood.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250605659867\\\/en\\\/2490220\\\/22\\\/Logo_Wedgewood.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio - Pharma Trend","og_description":"SWEDESBORO, N.J.–(BUSINESS WIRE)–#AnimalHealth–Wedgewood Pharmacy today announced the availability of a GS-441524 formula, a compounded oral antiviral formulation now part of its feline infectious peritonitis (FIP) treatment capabilities. With this addition, veterinarians can now prescribe both GS-441524 and Molnupiravir for their patients, two of the most requested compounded antivirals for FIP, through a single trusted source ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/","og_site_name":"Pharma Trend","article_published_time":"2025-06-05T17:06:19+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250605659867\/en\/2490220\/22\/Logo_Wedgewood.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio","datePublished":"2025-06-05T17:06:19+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/"},"wordCount":542,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250605659867\/en\/2490220\/22\/Logo_Wedgewood.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/","url":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/","name":"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250605659867\/en\/2490220\/22\/Logo_Wedgewood.jpg","datePublished":"2025-06-05T17:06:19+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250605659867\/en\/2490220\/22\/Logo_Wedgewood.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250605659867\/en\/2490220\/22\/Logo_Wedgewood.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/wedgewood-pharmacy-adds-gs-441524-to-its-fip-treatment-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Wedgewood Pharmacy Adds GS-441524 to Its FIP Treatment Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61380","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61380"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61380\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61380"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61380"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61380"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}